BiondVax up on exclusive license for antibody development, sale

Scinai Immunotherapeutics

05/06/2023 14:59

** U.S.-listed shares of biopharmaceutical company BiondVax
Pharmaceuticals Ltd  BVXV.O  up 24.1% at $2.11
    ** Co signs exclusive license agreement for development and
commercialization of a novel anti-IL-17 antibody for treatment
of autoimmune and inflammatory diseases, including psoriasis
    ** Comes as a part of ongoing collaboration with Max Planck
Society and University Medical Center Gottingen
    ** Says it plans to "initiate a preclinical in vivo efficacy
study in 2024 followed later by human clinical trials 
    ** As of last close, U.S.-listed shares of BVXV down 42.6%
YTD
    

 (Reporting by Saikeerthi in Bengaluru)
 ((Saikeerthi@thomsonreuters.com;))